Professional
Added to YB: 2026-04-14
Pitch date: 2026-04-10
ABVX [neutral]
ABIVAX Société Anonyme
-1.41%
current return
Author Info
Company Info
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Market Cap
EUR 8.5B
Pitch Price
EUR 106.30
Price Target
N/A
Dividend
N/A
EV/EBITDA
-32.84
P/E
-22.32
EV/Sales
1.8K
Sector
Biotechnology
Category
special_situation
Cedar Grove Capital Management Portfolio Holding: Abivax
ABVX (holding update): French biotech w/ obefazimod for ulcerative colitis. P3 data July '24 shows better efficacy, delivery, tolerability & safety vs JAK inhibitors/TNF-alpha blockers. Rumors of $15-$20B buyout pre-maintenance data (summer '25). Recently hired CCO for commercialization if no deal. Attractive takeover target given limited quality UC drug assets.
Read full article (1 min)